Do we need more psoriasis therapies?

The Lancet

Volumn 386, Issue 9993, 2015, Pages 512-514

  Lebwohl, Mark ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPSORIASIS AGENT; APREMILAST; BRODALUMAB; CERTOLIZUMAB PEGOL; CYCLOSPORIN A; ETANERCEPT; ETRETIN; FUMARIC ACID DERIVATIVE; GOLIMUMAB; INTERLEUKIN 17 ANTIBODY; IXEKIZUMAB; METHOTREXATE; METHOXSALEN; SECUKINUMAB; TOFACITINIB; TUMOR NECROSIS FACTOR INHIBITOR; USTEKINUMAB; IMMUNOGLOBULIN G; NONSTEROID ANTIINFLAMMATORY AGENT; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; TUMOR NECROSIS FACTOR RECEPTOR;

BIOLOGICAL THERAPY; HEALTH CARE NEED; HUMAN; LYMPHOCYTE COUNT; NOTE; PRIORITY JOURNAL; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; PSORIATIC ARTHRITIS; PUVA; SYSTEMIC THERAPY; TOPICAL TREATMENT; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION; FEMALE; MALE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; PIPERIDINES; PROTEIN KINASE INHIBITORS; PSORIASIS; PYRIMIDINES; PYRROLES; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 84938984361     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(15)60205-7     Document Type: Note

References (13)

1. S Gutierrez-Ureña, JF Molina, CO García, ML Cuéllar, LR Espinoza Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis Arthritis Rheum 39 1996 272 276
2. T Bongartz, AJ Sutton, MJ Sweeting, I Buchan, EL Matteson, V Montori Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials JAMA 295 2006 2275 2285
3. RG Langley, M Lebwohl, GG Krueger on behalf of the PHOENIX 2 Investigators Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up Br J Dermatol 172 2015 1371 1383
4. MC Hochberg, MG Lebwohl, SE Plevy, KF Hobbs, DE Yocum The benefit/risk profile of TNF-blocking agents: findings of a consensus panel Semin Arthritis Rheum 34 2005 819 836
5. G Brown, M Malakouti, E Wang, JY Koo, E Levin Anti-IL-17 phase II data for psoriasis: a review J Dermatolog Treat 26 2015 32 36
6. MG Lebwohl, H Bachelez, J Barker et al. Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey J Am Acad Dermatol 70 2014 871 881
7. EC Levin, R Gupta, G Brown, M Malakouti, J Koo Biologic fatigue in psoriasis J Dermatolog Treat 25 2014 78 82
8. K Abuabara, J Wan, AB Troxel et al. Variation in dermatologist beliefs about the safety and effectiveness of treatments for moderate to severe psoriasis J Am Acad Dermatol 68 2013 262 269
9. AB Gottlieb, RT Matheson, A Menter et al. Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study J Drugs Dermatol 12 2013 888 897
10. H Bachelez, PCM van de Kerkhof, R Strohal for the OPT Compare Investigators Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial Lancet 2015 published online June 5. http://dx.doi.org/10.1016/S0140-6736(14)62113-9
11. AB Kimball, D Gladman, JM Gelfand for the National Psoriasis Foundation National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening J Am Acad Dermatol 58 2008 1031 1042
12. WG Dixon, KD Watson, M Lunt et al. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology biologics register Arthritis Rheum 56 2007 2905 2912
13. SK Kurd, AB Troxel, P Crits-Christoph, JM Gelfand The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study Arch Dermatol 146 2010 891 895